Showing 1489 results
-
Press release /New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Ad hoc release /Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
-
Press release /New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
-
Press release /Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will…
-
Press release /CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
-
Press release /Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
-
Press release /Primary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to…
-
Press release /Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
-
Press release /In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen…